Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.

Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.

A high-fat diet disrupts the biology of the gut’s inner lining and its microbial communities — and promotes the production of a metabolite that may contribute to heart disease, according to a study published Aug. 13 in the journal Science.

The Structural Heart and Valve Center at Vanderbilt Heart and Vascular Institute (VHVI) has recently completed multiple groundbreaking transcatheter clinical trial procedures treating severe regurgitation of the mitral and tricuspid valves, a continuation of a decade of research that is revolutionizing the treatment of these conditions.

Vanderbilt researchers used genetics tools and biobanks with linked electronic health records to explore the associations between statins and noncardiovascular diseases.

Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material.

According to an innovative large-scale clinical trial reported last week in the New England Journal of Medicine, a single daily baby aspirin (81 mg) or a single daily adult aspirin (325 mg) are equally safe and effective for prevention of adverse cardiovascular events for patients with established atherosclerotic cardiovascular disease.